The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -167,795 |
| Depreciation | 2,084 |
| Stock-based compensation | 34,752 |
| Accretion of discount on marketable securities, net | 7,665 |
| Amortization of right-of-use asset | 182 |
| Prepaid expenses and other assets | 7,963 |
| Accounts payable | 272 |
| Accrued compensation | 2,374 |
| Accrued other expenses and other liabilities | 691 |
| Lease liability | -748 |
| Net cash used in operating activities | -143,816 |
| Purchases of marketable securities | 527,226 |
| Sales of marketable securities | 67,384 |
| Maturities of marketable securities | 427,308 |
| Purchases of property and equipment | 256 |
| Net cash (used in) provided by investing activities | -32,790 |
| Proceeds from issuance of common stock, net of offering costs | 187,362 |
| Exercise of stock options | 7,803 |
| Proceeds from employee stock purchase plan | 923 |
| Net cash provided by financing activities | 196,088 |
| Net change in cash and cash equivalents | 19,482 |
| Cash and cash equivalents at beginning of period | 41,666 |
| Cash and cash equivalents at end of period | 61,148 |
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)